Provided by Tiger Fintech (Singapore) Pte. Ltd.

INmune Bio Inc

8.12
-0.0200-0.25%
Post-market: 8.07-0.0465-0.57%18:07 EDT
Volume:218.49K
Turnover:1.76M
Market Cap:180.04M
PE:-3.72
High:8.18
Open:8.00
Low:7.89
Close:8.14
Loading ...

Company Profile

Company Name:
INmune Bio Inc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
14
Office Location:
225 NE Mizner Blvd.,Suite 640,Boca Raton,Florida,United States
Zip Code:
33432
Fax:
- -
Introduction:
INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Directors

Name
Position
Raymond J. Tesi
President and CEO, and Director
David Szymkowski
Director
Edgardo Baracchini
Director
J. Kelly Ganjei
Director
Marcia Allen
Director
Scott Juda
Director
Tim Schroeder
Director

Shareholders

Name
Position
David J. Moss
Chief Financial Officer, Treasurer and Secretary
Mark Lowdell
Chief Scientific Officer
Raymond J. Tesi
President and CEO, and Director